Skip to content

Real-World Study on Saccharomyces boulardii Powder as Adjunctive Therapy for Helicobacter pylori Eradication

Real-World Study on Saccharomyces boulardii Powder as Adjunctive Therapy for Helicobacter pylori Eradication

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500101599
Enrollment
Unknown
Registered
2025-04-27
Start date
2025-05-07
Completion date
Unknown
Last updated
2025-05-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter pylori

Interventions

Bioflor (Saccharomyces boulardii)-Adjunctive Treatment Group:None
Guideline-recommended regimens for Helicobacter pylori eradication Group:None
Other Prescription Probiotics-Adjunctive Treatment Group:None

Sponsors

The Third Xiangya Hospital of Central South University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
14 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Hp infected patients who have been confirmed by at least one standard testing method and have received eradication treatment; 2. Age 14-80 years old; 3. Patients who completed follow-up 1 month after treatment and had recorded results (successful or failed eradication).

Exclusion criteria

Exclusion criteria: 1. Patients with incomplete medical records and lack of basic data (such as treatment results, basic clinical factors); 2. Malignant tumors, pregnant or lactating patients, etc.; 3. Patients who have not received regular Hp therapy.

Design outcomes

Primary

MeasureTime frame
Helicobacter pylori eradication status;

Countries

China

Contacts

Public ContactFen Wang

Department of gastroenteropathy, The Third Xiangya Hospital of Central South University

wfen-judy@163.com+86 182 2997 5500

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026